Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions
Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct clinicopathologic disease from other types of diffuse large B-cell lymphoma (DLBCL) with unique prognostic features and limited availability of clinical data. The current standard treatment for newly diagnosed PMBCL has long been dependent on a dose-intensive, dose-adjusted multi-agent chemotherapy regimen of rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH). Recent randomized trials have provided evidence that R-CHOP followed by consolidation radiotherapy (RT) is a valuable alternative option to first-line treatment. For recurrent/refractory PMBCL (rrPMBCL), new drugs such as pembrolizumab and CAR-T cell therapy have proven to be effective in a few studies. Positron emission tomography-computed tomography (PET-CT) is the preferred imaging modality of choice for the initial phase of lymphoma treatment and to assess response to treatment. In the future, baseline quantitative PET-CT can be used to predict prognosis in PMBCL. This review focuses on the pathology of PMBCL, underlying molecular basis, treatment options, radiotherapy, targeted therapies, and the potential role of PET-CT to guide treatment choices in this disease..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in Oncology - 11(2021) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huan Chen [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| doi: |
10.3389/fonc.2021.654854 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ069084572 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ069084572 | ||
| 003 | DE-627 | ||
| 005 | 20230309082249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2021.654854 |2 doi | |
| 035 | |a (DE-627)DOAJ069084572 | ||
| 035 | |a (DE-599)DOAJc8196628b03341efbf3859d88e1054b0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a Huan Chen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct clinicopathologic disease from other types of diffuse large B-cell lymphoma (DLBCL) with unique prognostic features and limited availability of clinical data. The current standard treatment for newly diagnosed PMBCL has long been dependent on a dose-intensive, dose-adjusted multi-agent chemotherapy regimen of rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH). Recent randomized trials have provided evidence that R-CHOP followed by consolidation radiotherapy (RT) is a valuable alternative option to first-line treatment. For recurrent/refractory PMBCL (rrPMBCL), new drugs such as pembrolizumab and CAR-T cell therapy have proven to be effective in a few studies. Positron emission tomography-computed tomography (PET-CT) is the preferred imaging modality of choice for the initial phase of lymphoma treatment and to assess response to treatment. In the future, baseline quantitative PET-CT can be used to predict prognosis in PMBCL. This review focuses on the pathology of PMBCL, underlying molecular basis, treatment options, radiotherapy, targeted therapies, and the potential role of PET-CT to guide treatment choices in this disease. | ||
| 650 | 4 | |a primary mediastinal large B-cell lymphoma | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a targeted therapy | |
| 650 | 4 | |a mediastinal radiation | |
| 650 | 4 | |a positron emission tomography-computed tomography | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a Tao Pan |e verfasserin |4 aut | |
| 700 | 0 | |a Tao Pan |e verfasserin |4 aut | |
| 700 | 0 | |a Yizi He |e verfasserin |4 aut | |
| 700 | 0 | |a Ruolan Zeng |e verfasserin |4 aut | |
| 700 | 0 | |a Yajun Li |e verfasserin |4 aut | |
| 700 | 0 | |a Liming Yi |e verfasserin |4 aut | |
| 700 | 0 | |a Hui Zang |e verfasserin |4 aut | |
| 700 | 0 | |a Siwei Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Qintong Duan |e verfasserin |4 aut | |
| 700 | 0 | |a Ling Xiao |e verfasserin |4 aut | |
| 700 | 0 | |a Hui Zhou |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Oncology |d Frontiers Media S.A., 2012 |g 11(2021) |w (DE-627)DOAJ000099678 |x 2234943X |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fonc.2021.654854 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/c8196628b03341efbf3859d88e1054b0 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fonc.2021.654854/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2234-943X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 | ||